新加坡较短疗程的耐多药结核病治疗方案：东南亚患者适用吗？ - Suppr

Suppr

超能文献

The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?

作者信息

Chee Cynthia B E, KhinMar Kyi-Win, Sng Li-H, Jureen Roland, Cutter Jeffery, Lee Vernon J M, Wang Yee-Tang

机构信息

Respiratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore

Tuberculosis Control Unit, Tan Tock Seng Hospital, Singapore, Singapore.

出版信息

Eur Respir J. 2017 Aug 10;50(2). doi: 10.1183/13993003.00753-2017. Print 2017 Aug.

DOI:10.1183/13993003.00753-2017

PMID:28798092

Abstract

摘要

相似文献

The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?新加坡较短疗程的耐多药结核病治疗方案：东南亚患者适用吗？

Eur Respir J. 2017 Aug 10;50(2). doi: 10.1183/13993003.00753-2017. Print 2017 Aug.

Shorter regimen for multi drug resistant tuberculosis cures more than 80% of patients.针对耐多药结核病的短程治疗方案可治愈超过80%的患者。

BMJ. 2016 Oct 27;355:i5807. doi: 10.1136/bmj.i5807.

Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.在欧盟，对耐多药结核病进行更短疗程治疗的资格。

Eur Respir J. 2017 Mar 22;49(3). doi: 10.1183/13993003.01992-2016. Print 2017 Mar.

Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis.采用 9 个月方案治疗耐多药结核病的预期效果：基于人群的建模分析。

Lancet Respir Med. 2017 Mar;5(3):191-199. doi: 10.1016/S2213-2600(16)30423-4. Epub 2016 Dec 16.

Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.世界卫生组织推荐的新的较短疗程在一个耐多药结核病高负担国家的适用性。

Eur Respir J. 2017 Jan 3;49(1). doi: 10.1183/13993003.01967-2016. Print 2017 Jan.

Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.用更少的时间实现更快治疗：耐多药结核病的新型“短程”治疗方案

Eur Respir J. 2016 Nov;48(5):1503-1507. doi: 10.1183/13993003.01249-2016. Epub 2016 Sep 1.

Is Shorter Treatment Regimen for Multidrug-resistant Tuberculosis feasible in Indian Children?针对印度儿童的耐多药结核病短疗程治疗方案是否可行？

Indian Pediatr. 2017 Feb 15;54(2):160.

WHO recommendations on shorter treatment of multidrug-resistant tuberculosis.世界卫生组织关于缩短耐多药结核病治疗疗程的建议。

Lancet. 2016 Jun 18;387(10037):2486-7. doi: 10.1016/S0140-6736(16)30729-2.

[Consideration on the use of injectable anti-tuberculosis drufgs in the treatment of drug-resistant tuberculosis in china].关于在中国使用注射用抗结核药物治疗耐药结核病的思考

Zhonghua Jie He He Hu Xi Za Zhi. 2019 Jun 12;42(6):401-404. doi: 10.3760/cma.j.issn.1001-0939.2019.06.001.

Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.2000 - 2015年巴西耐多药结核病“较短”治疗方案中所用药物的耐药情况

Eur Respir J. 2017 Apr 12;49(4). doi: 10.1183/13993003.02309-2016. Print 2017 Apr.

引用本文的文献

Assessment of burden of drug-resistant tuberculosis at a tertiary care centre in northern India: a prospective single centre cohort study.印度北部一家三级医疗中心耐药结核病负担评估：一项前瞻性单中心队列研究。

BMJ Open. 2021 Apr 15;11(4):e044096. doi: 10.1136/bmjopen-2020-044096.

Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review.巴基斯坦耐多药结核病患者更短治疗方案的疗效：一项多中心回顾性病历研究。

Am J Trop Med Hyg. 2021 Mar 15;104(5):1784-1791. doi: 10.4269/ajtmh.20-1134.

Implementation of multidrug-resistant tuberculosis (MDR-TB) treatment in Gabon: lessons learnt from the field.加蓬耐多药结核病（MDR-TB）治疗的实施情况：来自现场的经验教训。

Infection. 2019 Oct;47(5):811-816. doi: 10.1007/s15010-019-01314-5. Epub 2019 May 9.

Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic.在孟买的一家大型私人诊所，很少有符合新推荐的短程耐多药结核病方案条件的人。

BMC Infect Dis. 2019 Jan 28;19(1):94. doi: 10.1186/s12879-019-3726-8.

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.地拉米胺、利奈唑胺、左氧氟沙星和吡嗪酰胺用于治疗氟喹诺酮敏感的耐多药结核病患者（使用现有和新药缩短耐多药结核病治疗时间，MDR-END）：一项II/III期、多中心、随机、开放标签临床试验的研究方案

Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1.

Tuberculosis elimination: where are we now?结核病消除：我们现在在哪里？

Eur Respir Rev. 2018 Jun 13;27(148). doi: 10.1183/16000617.0035-2018. Print 2018 Jun 30.

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.用于治疗耐多药和广泛耐药结核病的新型及重新利用的药物。

J Bras Pneumol. 2018 Apr;44(2):153-160. doi: 10.1590/s1806-37562017000000436.

本文引用的文献

Eur Respir J. 2017 Apr 12;49(4). doi: 10.1183/13993003.02309-2016. Print 2017 Apr.

World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.《世界卫生组织耐药结核病治疗指南（2016年更新版）》

Eur Respir J. 2017 Mar 22;49(3). doi: 10.1183/13993003.02308-2016. Print 2017 Mar.

Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.在欧盟，对耐多药结核病进行更短疗程治疗的资格。

Eur Respir J. 2017 Mar 22;49(3). doi: 10.1183/13993003.01992-2016. Print 2017 Mar.

Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule?欧盟东部地区的耐多药结核病：较短的疗程是例外还是常规？

Thorax. 2017 Sep;72(9):850-852. doi: 10.1136/thoraxjnl-2016-209841. Epub 2017 Feb 16.

Eur Respir J. 2017 Jan 3;49(1). doi: 10.1183/13993003.01967-2016. Print 2017 Jan.

Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.较短疗程耐多药结核病治疗方案的适用标准：世界卫生组织建议中的模糊之处

Am J Respir Crit Care Med. 2016 Oct 15;194(8):1028-1029. doi: 10.1164/rccm.201605-1080LE.

Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.欧洲新型较短疗程耐多药结核病治疗方案的获益有限。

Am J Respir Crit Care Med. 2016 Oct 15;194(8):1029-1031. doi: 10.1164/rccm.201606-1097LE.

Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.用更少的时间实现更快治疗：耐多药结核病的新型“短程”治疗方案

Eur Respir J. 2016 Nov;48(5):1503-1507. doi: 10.1183/13993003.01249-2016. Epub 2016 Sep 1.

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.基于人群的结核分枝杆菌分离株对吡嗪酰胺和氟喹诺酮类药物的耐药性：一项多国监测项目的结果

Lancet Infect Dis. 2016 Oct;16(10):1185-1192. doi: 10.1016/S1473-3099(16)30190-6. Epub 2016 Jul 7.

Molecular and Growth-Based Drug Susceptibility Testing of Mycobacterium tuberculosis Complex for Ethambutol Resistance in the United States.美国结核分枝杆菌复合群乙胺丁醇耐药性的分子与基于生长的药敏试验

Tuberc Res Treat. 2016;2016:3404860. doi: 10.1155/2016/3404860. Epub 2016 Jun 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验